Vis enkel innførsel

dc.contributor.authorWillmann, Jonas
dc.contributor.authorAppelt, L.
dc.contributor.authorBalermpas, Panagiotis
dc.contributor.authorBaumert, G.
dc.contributor.authorde Ruysscher, Dirk
dc.contributor.authorHoyer, Morten
dc.contributor.authorHurkmans, Coen
dc.contributor.authorKaidar-Person, Orit
dc.contributor.authorMeattini, Icro
dc.contributor.authorNiyazi, Maximilian
dc.contributor.authorPoortmans, Philip
dc.contributor.authorReynaert, Nick
dc.contributor.authorTandini-Lang, Stephanie
dc.contributor.authorvan der Linden, Yvette
dc.contributor.authorNieder, Carsten
dc.contributor.authorAndratschke, Nicolaus
dc.date.accessioned2023-12-21T13:12:27Z
dc.date.available2023-12-21T13:12:27Z
dc.date.issued2023-10-06
dc.description.abstractBackground: Re-irradiation is an increasingly utilized treatment for recurrent, metastatic or new malignancies after previous radiotherapy. It is unclear how re-irradiation is applied in clinical practice. We aimed to investigate the patterns of care of re-irradiation internationally.<p> <p>Material/Methods: A cross-sectional survey conducted between March and September 2022. The survey was structured into six sections, each corresponding to a specific anatomical region. Participants were instructed to complete the sections of their clinical expertise. A total of 15 multiple-choice questions were included in each section, addressing various aspects of the re-irradiation process. The online survey targeted radiation and clinical oncologists and was endorsed by the European Society for Radiotherapy and Oncology (ESTRO) and the European Organisation for Research and Treatment of Cancer (EORTC). <p>Results: 371 physicians from 55 countries across six continents participated. Participants had a median professional experience of 16 years, and the majority (60%) were affiliated with an academic hospital. The brain region was the most common site for re-irradiation (77%), followed by the pelvis (65%) and head and neck (63%). Prolonging local control was the most common goal (90–96% across anatomical regions). The most common minimum interval between previous radiotherapy and re-irradiation was 6–12 months (45–55%). Persistent grade 3 or greater radiation-induced toxicity (77–80%) was the leading contraindication. Variability in organs at risk dose constraints for re-irradiation was observed. Advanced imaging modalities and conformal radiotherapy techniques were predominantly used. A scarcity of institutional guidelines for re-irradiation was reported (16–19%). Participants from European centers more frequently applied thoracic and abdominal re-irradiation. Indications did not differ between academic and non-academic hospitals. <p>Conclusion: This study highlights the heterogeneity in re-irradiation practices across anatomical regions and emphasizes the need for high-quality evidence from prospective studies to guide treatment decisions and derive safe cumulative dose constraints.en_US
dc.identifier.citationWillmann, Appelt, Balermpas, Baumert, de Ruysscher, Hoyer, Hurkmans, Kaidar-Person, Meattini, Niyazi, Poortmans, Reynaert, Tandini-Lang, van der Linden, Nieder, Andratschke. Re-irradiation in clinical practice: Results of an international patterns of care survey within the framework of the ESTRO-EORTC E2-RADIatE platform. Radiotherapy and Oncology. 2023;189en_US
dc.identifier.cristinIDFRIDAID 2193672
dc.identifier.doi10.1016/j.radonc.2023.109947
dc.identifier.issn0167-8140
dc.identifier.issn1879-0887
dc.identifier.urihttps://hdl.handle.net/10037/32201
dc.language.isoengen_US
dc.publisherElsevieren_US
dc.relation.journalRadiotherapy and Oncology
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2023 The Author(s)en_US
dc.rights.urihttps://creativecommons.org/licenses/by/4.0en_US
dc.rightsAttribution 4.0 International (CC BY 4.0)en_US
dc.titleRe-irradiation in clinical practice: Results of an international patterns of care survey within the framework of the ESTRO-EORTC E2-RADIatE platformen_US
dc.type.versionpublishedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Attribution 4.0 International (CC BY 4.0)
Med mindre det står noe annet, er denne innførselens lisens beskrevet som Attribution 4.0 International (CC BY 4.0)